Tissue Engineering And Nanotheranostics

“9.61x6.69” b2815 Tissue Engineering and Nanotheranostics

Multifunctional Nanomaterials for Cancer Theranostics 265

131. Pisani MJ, Wheate NJ, Keene FR, Aldrich­Wright JR, Collins JG.
     Anionic PAMAM dendrimers as drug delivery vehicles for transition
     metal­based anticancer drugs. J. Inorg. Biochem. 103 , 373–380
     (2009).


132. Jiang YY, Tang GT, Zhang LH, Kong SY, Zhu SJ, Pei YY. PEGylated
     PAMAM dendrimers as a potential drug delivery carrier: In vitro and
     in vivo comparative evaluation of covalently conjugated drug and non­
     covalent drug inclusion complex. J. Drug Targeting 18 , 389–403
     (2010).


133. Yellepeddi VK, Kumar A, Palakurthi S. Biotinylated poly(amido)amine
     (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer
     cells in vitro. Anticancer Res. 29 , 2933–2943 (2009).


134. Dutta T, Agashe HB, Garg M, Balakrishnan P, Kabra M, Jain NK. Poly
     (propyleneimine) dendrimer based nanocontainers for targeting of
     efavirenz to human monocytes/macrophages in vitro. J. Drug
     Targeting 15 , 89–98 (2007).


135. Patel HK, Gajbhiye V, Kesharwani P, Jain NK. Ligand anchored
     poly(propyleneimine) dendrimers for brain targeting: Comparative in
     vitro and in vivo assessment. J. Colloid. Int. Sci. 482 , 142–150 (2016).


136. Kuo JH, Jan MS, Lin YL. Interactions between U­937 human mac­
     rophages and poly(propyleneimine) dendrimers. J Control. Rel. 120 ,
     51–59 (2007).


137. Kesharwani P, Tekade RK, Jain NK. Generation dependent cancer
     targeting potential of poly(propyleneimine) dendrimer. Biomaterials
     35 , 5539–5548 (2014).


138. Li W, Huang L, Ying X, Jian Y, Hong Y, Hu F, Du Y. Antitumor drug
     delivery modulated by a polymeric micelle with an upper critical solu­
     tion temperature. Angewandte Chemie 54 , 3126–3131 (2015).


139. Lu HL, Syu WJ, Nishiyama N, Kataoka K, Lai PS. Dendrimer phthalocy­
     anine­encapsulated polymeric micelle­mediated photochemical inter­
     nalization extends the efficacy of photodynamic therapy and overcomes
     drug­resistance in vivo. J. Control. Rel. 155 , 458–464 (2011).


140. Mei H, Shi W, Pang Z, Wang H, Lu W, Jiang X, Deng J, Guo T, Hu
     Y. EGFP­EGF1 protein­conjugated PEG­PLA nanoparticles for tissue
     factor targeted drug delivery. Biomaterials 31 , 5619–5626 (2010).


141. Dou S, Yang XZ, Xiong MH, Sun CY, Yao YD, Zhu YH, Wang J.
     ScFv­decorated PEG­PLA­based nanoparticles for enhanced siRNA
     delivery to Her2(+) breast cancer. Adv. Health. Mater. 3 , 1792–1803
     (2014).